Genetic Variants and Regulation of Specialized Pro-resolving Mediator
Identifying the Effect of Genetic Variants on Specialized Pro-resolving Mediators and Their Association With Chronic Inflammatory Conditions
Queen Mary University of London
200 participants
May 6, 2021
OBSERVATIONAL
Conditions
Summary
Inflammation is the way that the body reacts against infection, injury or illness. An uncontrolled inflammatory response can lead to the development of inflammatory diseases, such as rheumatoid arthritis and cardiovascular conditions. Recent studies have shown that inflammation is a regulated process coordinated by a group of molecules known as specialized pro-resolving mediator (SPM). These molecules are produced by enzymes via the enzymatic conversion of essential fatty acids; whereas their biological actions are mediated by proteins expressed on the surface of cells known as receptors. Given the central role that pro-resolving mediators play in regulating the immune response, the aim of this study is to investigate whether there are genetic variants (mutations) in genes encoding for enzymes and receptors involved in the biology of these molecules and to determine how these mutations affect SPM's activity or function. Findings made as part of these studies will help shed light into mechanism influencing disease onset and/or progression and potentially enhance the discovery of new and more effective treatments.
Eligibility
Inclusion Criteria1
- Current volunteer of the Genes \& Health program with (test) or without (control) relevant genetic mutations. Genes \& Health is a huge long-term study of 100,000 people of Bangladeshi and Pakistani origin focuses to link genes with health records and to study disease and treatments. When a volunteer participates in this program, they agree to the possibility to be invited for further studies. Gene \& Health program invites volunteers to take part in two regions of the UK: East London and Bradford.
Exclusion Criteria6
- Volunteer that has not had their genome sequenced after taking part in Stage 1 of Genes \& Health program.
- Volunteer with significant genetically inherited conditions.
- Any abnormality or pre-existing disease which, in the opinion of the investigator, might either expose the subject to risk, or influence the validity of the results.
- Volunteer that went under surgery and are recovering.
- Participation in a clinical study of a new chemical entity, biological product or a prescription medicine, or loss of more than 400 mL blood, within the previous 3 months.
- Presence or history of drug or alcohol abuse.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The blood donation will take place at the Gene \& Health clinical assessment centre facilities. A trained member from Gene \& Health program will be responsible for taking the blood samples.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04698291